pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . The post Zynteglo halt re-ignites viral vector safety concerns; analysts appeared first on.

Immunization 52

Immunization 52

pharmaphorum

JUNE 12, 2022

Cases of cancer associated with insertional mutagenesis, caused when the viral vectors used to deliver the gene therapy to host cells, have been seen with bluebird’s gene therapies but have been more apparent in trials involving its CALD and sickle cell disease candidates than beti-cel.

FDA 59

FDA 59

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Bluebird already uses a lentiviral vector in its approved gene therapy for beta-thalassemia called Zynteglo. Also known as lovo-cel, bluebird bio’s product is a lentiviral gene therapy.

FDA 59

FDA 59

Pharmaceutical Technology

MAY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

Viseven

JUNE 23, 2022

Metadata tagging allows searching for a needed piece of delivery faster and easier than usual research on the content subject. Modular content works perfectly for both cases, as it helps to collect the whole library of templates filled with unique meta tags for quick search.

Communication 52

Communication 52

pharmaphorum

NOVEMBER 19, 2021

Barely a week later, Moderna’s mRNA rival jab entered the fray, followed quickly by the AstraZeneca/Oxford University viral vector vaccine, and then this year, Janssen’s single-shot vaccine got its finger in the pie. Indeed, the price tags for Pfizer’s and Moderna’s jabs are substantial. Pfizer/BioNTech’s vaccine dominates the market.

Vaccines 137

Vaccines Communication 137

pharmaphorum

AUGUST 26, 2022

Roctavian delivers a working copy of the Factor VIII gene into cells via an adeno-associated virus (AAV) vector, and offers a one-shot, potentially curative therapy for haemophilia A. million spread over five years.

FDA 111

FDA 111